Monte Rosa Therapeutics (GLUE) Operating Leases (2022 - 2026)

Monte Rosa Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $34.6 million for Q1 2026.

• In Q1 2026, Operating Leases fell 8.99% year-over-year to $34.6 million; the TTM figure through Mar 2026 stood at $34.6 million (down 8.99% YoY), while the FY2025 annual figure was $34.8 million, down 10.79% from the prior year.
• Operating Leases was $34.6 million for Q1 2026 at Monte Rosa Therapeutics, down from $34.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $46.1 million in Q2 2022 to a low of $5.5 million in Q1 2022.
• Historically, Operating Leases has averaged $38.5 million across 5 years, with a median of $40.9 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Operating Leases surged 693.02% in 2023, then declined 10.79% in 2025.
• A 5-year view of Operating Leases shows it stood at $43.9 million in 2022, then slipped by 2.27% to $42.9 million in 2023, then declined by 9.04% to $39.0 million in 2024, then slipped by 10.79% to $34.8 million in 2025, then decreased by 0.61% to $34.6 million in 2026.
• The last three Operating Leases figures came in at $34.6 million (Q1 2026), $34.8 million (Q4 2025), and $35.9 million (Q3 2025), per Business Quant data.